Kezar Life Sciences to Present at the William Blair Biotech Focus Conference
07/07/2022 - 04:30 PM
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--
Kezar Life Sciences, Inc. KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that Noreen Roth Henig , M.D., Chief Medical Officer, will participate in a panel called “Developing Therapies Against Novel Targets in Autoimmune Diseases ” at the William Blair Biotech Focus Conference in New York, NY . The panel will be held in person on Wednesday, July 13, 2022 , at 11:00 am ET .
About Kezar Life Sciences
Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders. The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single, powerful targets. Zetomipzomib, its lead development asset, is a selective immunoproteasome inhibitor being evaluated in a Phase 2 clinical trial in lupus nephritis. This product candidate also has the potential to address multiple chronic immune-mediated diseases. KZR-261 is the first anti-cancer clinical candidate from the company’s platform targeting the Sec61 translocon and the protein secretion pathway. An open-label dose-escalation Phase 1 clinical trial of KZR-261 to assess safety, tolerability and preliminary tumor activity in solid tumors is underway. For more information, visit www.kezarlifesciences.com .
View source version on businesswire.com : https://www.businesswire.com/news/home/20220707005143/en/
Investor
Gitanjali Jain
gjain@kezarbio.com
Media
Liza Sullivan
Argot Partners
kezar@argotpartners.com
Source: Kezar Life Sciences, Inc.
Kezar Life Sciences Inc
NASDAQ:KZR
KZR Rankings
#5461 Ranked by Stock Gains
KZR Stock Data
Industry
Research and Development in Biotechnology
Sector
Professional, Scientific, and Technical Services
Tags
Health Technology, Biotechnology
Country
US
City
South San Francisco
About KZR
kezar life sciences, inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the united states. the company's lead product candidate is kzr-616, a selective immunoproteasome inhibitor that is in phase 2 clinical trials across five autoimmune indications, including lupus nephritis, autoimmune hemolytic anemia, immune thrombocytopenia, dermatomyositis, and polymyositis; and phase 1b/2 clinical trials in systemic lupus erythematosus and lupus nephritis. its preclinical products include kzr-616, a selective immunoproteasome inhibitor for the treatment of various autoimmune disease indications; and kzr-tbd for the treatment of oncology and autoimmunity. the company was founded in 2015 and is headquartered in south san francisco, california.
